Ratings MorphoSys AG Deutsche Boerse AG

Equities

MOR2

US6177602025

Market Closed - Deutsche Boerse AG Other stock markets 02:04:04 2024-07-12 am EDT			5-day change	1st Jan Change
16.9 ^EUR	+3.05%		+3.05%	+101.19%

Jul. 12	Novartis Seeks Squeeze Out Approval at MorphoSys AGM	MT
Jun. 26	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MORPHOSYS AG	+101.19%	2.78B	-
MODERNA, INC.	+22.10%	46.55B	B-
LONZA GROUP AG	+46.45%	41.84B	A
IQVIA HOLDINGS INC.	-3.12%	40.84B	B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B	B
CELLTRION, INC.	-6.30%	28.27B	C
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B	B-
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B	B+
MEDPACE HOLDINGS, INC.	+44.52%	13.69B	C+
BIO-TECHNE CORPORATION	+0.19%	12.18B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes